Home › NCT02325674

MEASuRE: Metreleptin Effectiveness And Safety Registry

RecruitingObservational study

Who can join

All ages · All sexes

Full eligibility criteria

Inclusion Criteria:

* Patients treated with metreleptin through commercial supply at the time or before enrolment into registry
* Patients who provide a written consent
* Patient coming off metreleptin clinical studies and continuing or restarting treatment with metreleptin through commercial supply

Exclusion Criteria:

• Patients currently treated with an investigational agent as part of a clinical trial

About the study

The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.

What is being tested

Metreleptin (drug)

Sponsor: Chiesi Farmaceutici S.p.A. · Participants: 100 · Started: Oct 11, 2016

Contact the study team

Lori Hartnett · Phone: +3905212791

Official record on ClinicalTrials.gov — NCT02325674

Locations in the U.S.

Illinois	Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Kansas	University of Kansas Medical Center Research Institute, Inc., Kansas City
Maryland	Nih/Niddk/Deob, Bethesda
Michigan	University of Michigan, Ann Arbor Childrens Hospital of Michigan, Detroit
Ohio	Endocrinology Research Associates, Columbus
Pennsylvania	Children's Hospital of Philadelphia, Philadelphia
Texas	UT Southwestern Medical Center, Dallas
Washington	Seattle Children's Hospital, Seattle

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.